O’Malley Reviews Standard Therapies for Patients with Platinum-Agnostic Ovarian Cancer
David M. O’Malley, MD, discusses the prognosis and historical treatment options for patients with platinum-agnostic ovarian cancer.
David M. O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center, discusses the prognosis and historical treatment options for patients with platinum-agnostic ovarian cancer.
According to O’Malley, there is a growing group of patients who are not eligible to platinum therapy due to either hypersensitive or treatment with the agent in the past. These patients are often no longer eligible for clinical trials.
When looking at this population group, the overall historical experience of this group is limited. This means that data on this population is equally limited, according to O’Malley. Patients who are platinum-agnostic are often treated with non-platinum containing agents, such as bevacizumab (Avastin).
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More
